Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + Capecitabine in Adjuvant Intrahepatic Cholangiocarcinoma
NCT04295317Phase 2Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2020
- Primary completion
- Jun 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Started Aug 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04295317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295317.